- $14.48m
- $19.60m
- $52.68m
Brief: Blueline Capital Partners LP Reports A 7.4 Pct Stake In Iridex As Of Feb. 14 - SEC Filing
Brief: Iridex Sees Q4 2018 Revenue $11 Million To $11.3 Million
Brief: Iridex announces departure of chief financial officer and reiterates full year 2018 guidance
Brief: IRIDEX Announces Q3 Revenue of $11.3 Million
Brief: IRIDEX Announces Appointment Of Robert Grove To Board
U.S. STOCKS ON THE MOVE-Iridex, NiSource, Blue Bird, Valvoline, Tandem Diabetes
U.S. STOCKS ON THE MOVE-Vital Therapies, Dave & Buster's Entertainment, Radiant Logistics, Genprex
U.S. STOCKS ON THE MOVE-Iridex, Sears, Applied Optoelectronics, Vital Therapies
Iridex Corp: Drops on deep discounted stock offering
Brief: IRIDEX Announces Pricing Of Public Offering Of Common Stock
Brief: Iridex Announces Proposed Public Offering Of Common Stock
Brief: Iridex Announces FDA Clearance For Updated Trufocus Lio Premiere Laser Accessory
Brief: Iridex Announces 2018 Second Quarter Results And Raises Full Year 2018 Guidance
Brief: Iridex Announces Approval Of Cyclo G6 Glaucoma Laser System In Korea
Brief: Iridex Corp Q1 Revenue $9.5 Million
Brief: Iridex Announces Availability Of G-Probe Illuminate Device In Europe
Brief: Iridex Qtrly Loss Per Share $0.44
Brief: Iridex Issues Voluntary Recall Of Trufocus Lio Premiere Laser Indirect Ophthalmoscope
Brief: Blueline Capital Partners LP Reports 8.5 pct Passive Stake In Iridex Corp As Of Dec. 31, 2017